RIGL Earnings
Latest Revenue78.7M
Latest Net Income17.3M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q2 2026 | $0.93 | 78.7M | 17.3M | -22.6% | -72.1% |
| Q1 2026 | $0.47 | 58.8M | 8.7M | +10.3% | -26.6% |
| Q4 2025 | $14.72 | 69.8M | 268.1M | +21.2% | +1,717.3% |
| Q3 2025 | $1.55 | 69.5M | 27.9M | +25.6% | +118.3% |
| Q2 2025 | $3.33 | 101.7M | 59.6M | +176.0% | +5,650.0% |
| Q1 2025 | $0.64 | 53.3M | 11.4M | +80.6% | +236.2% |
| Q4 2024 | $0.81 | 57.6M | 14.3M | +60.9% | +3,950.0% |
| Q3 2024 | $0.71 | 55.3M | 12.4M | +96.6% | +315.2% |
| Q2 2024 | -$0.06 | 36.8M | -1030000 | — | — |
| Q1 2024 | -$0.47 | 29.5M | -8247000 | — | — |
| Q4 2023 | $0.02 | 35.8M | 737.0K | — | — |
| Q3 2023 | -$0.33 | 28.1M | -5692000 | — | — |
Rigel Pharmaceuticals Inc. (New) (RIGL) — Earnings